Advertisement

International Journal of Clinical Pharmacy

, Volume 35, Issue 5, pp 683–687 | Cite as

Comparison of the prevalence of convulsions associated with the use of cefepime and meropenem

  • Akihiro TanakaEmail author
  • Kenshi Takechi
  • Shinichi Watanabe
  • Mamoru Tanaka
  • Katsuya Suemaru
  • Hiroaki Araki
Short Research Report

Abstract

Background The US Food and Drug Administration reported seizures associated with the use of cefepime (primarily in patients with renal impairment who did not receive appropriate dose adjustments of cefepime). Objective The maximum dose of cefepime in the USA (6 g per day) is higher than that in Japan (4 g per day). We investigated the prevalence of convulsions associated with the use of cefepime by comparing it with that of meropenem. Methods A retrospective study was undertaken in 183 patients treated with cefepime and 745 patients treated with meropenem over 2 years at Ehime University Hospital. Cefepime or meropenem-associated convulsions were defined according to the following criteria: (1) administration or dose escalation of diazepam, phenytoin, phenobarbital and thiamylal given via the intravenous route (2) convulsions recorded in medical records during administration of cefepime or meropenem. Results The prevalence of convulsions was significantly greater in the cefepime treated group than in the meropenem-treated group. Among the patients who had cefepime-associated convulsions, none had renal failure. Cefepime-associated convulsions occurred only in patients with brain disorders. Conclusion Cefepime-associated convulsions should be recognized as potential complications even in patients with normal renal function. Brain disorders may increase the risk of cefepime-associated convulsions.

Keywords

Brain disorder Cefepime Convulsion Meropenem Renal function 

Notes

Funding

None.

Conflicts of interest

The authors confirm that there are no conflicts of interest.

References

  1. 1.
    Yahav D, Paul M, Fraser A, Sarid N, Leibovici L. Efficacy and safety of cefepime: a systematic review and meta-analysis. Lancet Infect Dis. 2007;7:338–48.PubMedCrossRefGoogle Scholar
  2. 2.
    Matsuo S, Imai E, Horio M, Yasuda Y, Tomita K, Nitta K, et al. Revised equations for estimated GFR from serum creatinine in Japan. Am J Kidney Dis. 2009;53:982–92.PubMedCrossRefGoogle Scholar
  3. 3.
    Lamoth F, Buclin T, Pascual A, Vora S, Bolay S, Decosterd LA, et al. High cefepime plasma concentrations and neurological toxicity in febrile neutropenic patients with mild impairment of renal function. Antimicrob Agents Chemother. 2010;54:4360–7.PubMedCentralPubMedCrossRefGoogle Scholar
  4. 4.
    Norrby SR, Gildon KM. Safety profile of meropenem: a review of nearly 5,000 patients treated with meropenem. Scand J Infect Dis. 1999;31:3–10.PubMedCrossRefGoogle Scholar
  5. 5.
    Neu HC. Safety of cefepime: a new extended-spectrum parenteral cephalosporin. Am J Med. 1996;100:68S–75S.PubMedCrossRefGoogle Scholar
  6. 6.
    Sonck J, Laureys G, Verbeelen D. The neurotoxicity and safety of treatment with cefepime in patients with renal failure. Nephrol Dial Transplant. 2008;23:966–70.PubMedCrossRefGoogle Scholar
  7. 7.
    Kim SY, Lee IS, Park SL, Lee J. Cefepime neurotoxicity in patients with renal insufficiency. Ann Rehabil Med. 2012;36:159–62.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Maganti R, Jolin D, Rishi D, Biswas A. Nonconvulsive status epilepticus due to cefepime in a patient with normal renal function. Epilepsy Behav. 2006;8:312–4.PubMedCrossRefGoogle Scholar
  9. 9.
    Gangireddy VG, Mitchell LC, Coleman T. Cefepime neurotoxicity despite renal adjusted dosing. Scand J Infect Dis. 2011;43:827–9.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media Dordrecht 2013

Authors and Affiliations

  • Akihiro Tanaka
    • 1
    Email author
  • Kenshi Takechi
    • 1
  • Shinichi Watanabe
    • 1
  • Mamoru Tanaka
    • 1
  • Katsuya Suemaru
    • 2
  • Hiroaki Araki
    • 1
  1. 1.Division of PharmacyEhime University HospitalToonJapan
  2. 2.School of PharmacyShujitu UniversityOkayamaJapan

Personalised recommendations